Aeromexico Named the Most On-Time Global Airline in 2024:

 LONDON - Thursday, 02. January 2025

Results For the Best On-Time Airlines and Airports of 2024 Revealed by Cirium

Mexico’s flag carrier topped the global category, followed by Saudia, and Delta Air Lines

Regional Winners Include: Copa Airlines (Latin America), Delta Air Lines (North America), Iberia Express (Europe, and Low-Cost Airline), Japan Airlines (Asia-Pacific), and Safair (Middle East and Africa)

Riyadh King Khalid International Airport in Saudi Arabia Named Most On-Time Global Airport for 2024

 

(BUSINESS WIRE) -- Cirium, the world’s most trusted source of aviation analytics, today announced the winners of its 2024 On-Time Performance Review, celebrating airlines and airports that excelled in on-time and operational performance.

Cirium’s Annual report is the gold standard for global airline and airport performance analytics. An on-time flight is defined as a flight that arrives within 14:59 minutes of the scheduled gate arrival time. Airports measure punctuality as departing flights within 14:59 minutes of their scheduled departure time.

Mexico’s Flag Carrier Tops Global Rankings

Aeromexico claimed the prestigious title of the most On-Time “Global Airline” in 2024, achieving an impressive On-Time performance rate of 86.70%. Saudia followed closely as the runner-up with 86.35%, while Delta Air Lines secured third place with 83.46%, continuing to showcase its operational reliability on the world stage.

Cirium’s Annual Review also acknowledges the operational excellence of airlines across the world, with five regional awards. Iberia Express, member of the International Airlines Group, had success as both the most On-Time airline in Europe, and the most On-Time Low-Cost airline globally. Japan Airlines ranked first within Asia-Pacific, just slightly ahead of All Nippon Airways.

Delta Air Lines continued its dominance in North America, while Copa Airlines achieved a landmark 10th win in Latin America. Safair’s also won most On-Time airline in the Middle East and Africa. The full tables of results by region and category are presented below.

Riyadh’s King Khalid Airport Takes Top Honors in the Global Airport Category

In the Airport categories, Riyadh King Khalid International Airport, the gateway to Saudi Arabia’s capital, claimed this year’s prestigious title of the most On-Time “Global Airport” with an impressive 86.65% of flights departing on time. The Middle Eastern hub further distinguished itself by securing victory in the ‘Large Airport’ category, outperforming top contenders from around the world.

The title of most On-Time ‘Medium Airport’ was awarded to Panama’s Tocumen International Airport - the home base for Latin American winner Copa Airlines, while the ‘Small Airport’ winner was Guayaquil Jose Joaquin de Olmedo International Airport in Ecuador.

Special Recognition of Operational Excellence: The Cirium Platinum Awards

Delta Air Lines topped the table for a fourth consecutive year, landing Cirium’s Platinum Award for global operational excellence. This prestigious accolade comes as the Atlanta-based airline continues to be praised for its unwavering commitment to operational performance.

The Platinum award considers the complexity of the carrier’s network, volume of flights, and the ability to limit the impact of flight disruptions on passengers over the entire year. The airline was recognized for its on-time performance over the course of 2024 at 83.46%, on more than 1,712,529 total flights in 2024.

This year, Cirium also presented its first annual Platinum Award to a global airport, with El Dorado International Airport in Bogotá, Colombia receiving this prestigious award. The Airport Platinum Award considers a broader range of factors including the impact of delays on passengers, the duration of disruptions, operational complexity, and the airport’s appeal, with a particular focus on growth. This holistic approach highlights excellence across multiple dimensions, setting a new benchmark in airport performance evaluation.

Jeremy Bowen, Cirium CEO, said: “In an industry defined by operational complexity, we are extremely proud to be celebrating the airlines and airports who have provided customers the most on-time flights and best performance in 2024, acknowledging their operational excellence.”

“2024 was a difficult year for airlines, facing a large-scale IT outage, and unseasonable and severe weather patterns. Despite these challenges, these airlines and airports have worked tirelessly to ensure their customers have a smooth journey and reach their destination on-time.”

“We extend our congratulations to all the winners of this year’s On-Time Performance Review, each of whom has set new standards in operational excellence. A special recognition goes to Delta Air Lines for continuing their outstanding winning streak with Cirium’s Platinum Award for airlines, Copa Airlines for achieving its 10th title as Latin America’s most On-Time airline, Iberia Express for its consistent performance as Europe’s most On-Time airline, and Bogotá El Dorado Airport for securing Cirium’s first-ever Platinum Award for an airport.”

Now in its 16th year, the Cirium On-Time Performance Review remains the definitive benchmark for monitoring global airline operational performance. Powered by Cirium’s vast and impartial data—sourced from over 600 real-time feeds, including airlines, airports, global distribution systems, and civil aviation authorities—it offers a thorough and objective view of the industry. The program is further strengthened by the guidance of an independent advisory board composed of seasoned industry experts with decades of experience.

Cirium’s full 2024 On-Time Performance Review is available to view and download at www.cirium.com/on-time-performance.

Notes to editors:

The results for 2024 for the top ten performers in all categories include the following:

Global Airline leaders were:

Rank	Airline Code	Airline Name	On-Time Performance (OTP)
1	AM	Aeroméxico	86.70%
2	SV	Saudia	86.35%
3	DL	Delta Air Lines	83.46%
4	LA	LATAM Airlines	82.89%
5	QR	Qatar Airways	82.83%
6	AD	Azul Airlines	82.42%
7	AV	Avianca	81.80%
8	IB	Iberia	81.58%
9	SK	Scandinavian Airlines	81.40%
10	UA	United Airlines	80.93%

In Europe the leading airlines were:

Rank	Airline Code	Airline Name	On-Time Performance (OTP)
1	I2	Iberia Express	84.69%
2	IB	Iberia	81.58%
3	SK	Scandinavian Airlines	81.40%
4	VY	Vueling Airlines	81.20%
5	DY	Norwegian	79.23%
6	UX	Air Europa	78.99%
7	OS	Austrian Airlines	78.72%
8	SN	Brussels Airlines	77.77%
9	LO	LOT Polish Airlines	77.72%
10	D8	Norwegian Air Sweden	76.04%

In North America the leading airlines were:

Rank	Airline Code	Airline Name	On-Time Performance (OTP)
1	DL	Delta Air Lines	83.46%
2	UA	United Airlines	80.93%
3	AS	Alaska Airlines	79.25%
4	AA	American Airlines	77.78%
5	WN	Southwest Airlines	77.77%
6	NK	Spirit Airlines	76.05%
7	B6	JetBlue Airlines	74.53%
8	F9	Frontier Airlines	71.57%
9	AC	Air Canada	71.36%
10	WS	WestJet	70.99%

In Asia Pacific the leading airlines were:

Rank	Airline Code	Airline Name	On-Time Performance (OTP)
1	JL	Japan Airlines	80.90%
2	NH	All Nippon Airways	80.62%
3	SQ	Singapore Airlines	78.67%
4	NZ	Air New Zealand	77.58%
5	FD	Thai AirAsia	77.46%
6	VN	Vietnam Airlines	76.70%
7	PR	Philippine Airlines	76.06%
8	GA	Garuda Indonesia Airlines	75.30%
9	CX	Cathay Pacific Airlines	75.19%
10	QF	Qantas Airways	73.93%

In Latin America the leading airlines were:

Rank	Airline Code	Airline Name	On-Time Performance (OTP)
1	CM	Copa Airlines	88.22%
2	AM	Aeroméxico	86.70%
3	BW	Caribbean Airlines	85.47%
4	G3	Gol Linhas Aereas	84.09%
5	AR	Aerolineas Argentinas	83.06%
6	LA	LATAM Airlines	82.89%
7	AD	Azul Airlines	82.42%
8	AV	Avianca	81.80%
9	H2	Sky Airlines	76.67%
10	JA	JetSmart Chile	73.23%

In the Middle East and Africa the leading airlines were:

About Cirium

Cirium® is the world’s most trusted source of aviation analytics. The company delivers powerful data and cutting-edge analytics to empower a wide spectrum of industry players. Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities with the clarity and intelligence they need to optimize their operations, make informed decisions, and accelerate revenue growth.

Cirium® is part of LexisNexis® Risk Solutions, a RELX business, which provides information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium® on LinkedIn or visit cirium.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250101214982/en/

Permalink

https://www.aetoswire.com/en/news/0201202543793

Contacts

For Cirium media inquiries please contact media@cirium.com

Dabur International backs EAGAFEST 2024 to encourage Ayurveda in UAE

Dubai, United Arab Emirates - Thursday, 02. January 2025 AETOSWire

Reiterating its commitment towards making Ayurveda a reliable choice for health and well-being across nations; Dabur International, with its 138 years of rich legacy, joined forces with EAGAFEST 2024.

Held at Crown Plaza, Deira the Emirates Ayurvedic Graduates Association (EAGA) celebrated and honoured the ancient science of holistic health and balanced living. As pioneers in revolutionizing Ayurvedic products across an array of essentials like personal care, oral care, hair care, and health supplements; Dabur International plays a pivotal in upholding the principles of Ayurveda.

Ayurveda is perceived as one of the most ancient well-documented systems of medicine equally relevant in modern times. Its holistic approach and unique healing processes honor it with an indomitable position as the ‘Science of Life’. A system of holistic health, it is increasingly being recognized, respected, and adopted for its ability to alleviate disease and improve physical and mental well-being. While Dabur International has been successfully integrating Ayurveda with its efficacious product offerings through its wide knowledge base and modern adaptations of traditional procedures; it also encourages organisations like EAGA that promote the adoption of Ayurveda beyond academics.

EAGAFEST 2024 witnessed over 250 Ayurveda practitioners celebrate the essence of these traditional medicine methods fostering mutually beneficial and long-lasting associations to promote Ayurveda’s growing relevance in the Middle East. This festival is a testament to the institutes commitment to cultural heritage and professional unity. Speaking of its association with EAGAFEST, Dabur spokesperson said; “The healing power of Ayurveda is now being widely recognized across countries and we are certainly proud of EAGA’s dedication towards promoting Ayurveda in the Middle East. With our extensive portfolio of Ayurveda-based natural products like Honitus (for sore throat), Rapidex (for pain relief), Tulsi drops (immunity booster), etc. we have mapped several continents to provide communities with safe, natural, and healing alternatives. Ayurveda is close to nature, sustainable, and cruelty-free, and inculcates healing processes beyond the visible. We are committed to helping Ayurveda take center stage globally and will continue to collaborate with such congregations that focus on Ayurveda as a natural way of life.”

Sharing his views, Dr. Shyam, a key personnel member from EAGA said; “The prestigious EAGA is the largest association of dedicated Ayurveda doctors in the UAE and we’re elated that our passion is further fuelled by Dabur’s support. Dabur is a household name back in India and is fast gaining recognition across the world. When a stalwart brand like Dabur joins hands with professional institutions like us, it is going to deepen and widen Ayurveda’s positive impact.”

Going further, Dabur International intends to continue supporting academia as well as organizations of Ayurveda practitioners for the authentic and widespread acceptance of Ayurveda.

Permalink
https://www.aetoswire.com/en/news/0201202543794

Contacts

Namita Thakkar

namita@matrixdubai.com

Nawy and Truecaller Partner to Elevate Customer Experience With Safe, Efficient, and Trusted Business Communication.

 CAIRO - Monday, 30. December 2025

With the Truecaller Customer Experience[CX] solution, Nawy provides users with a trusted, verified, and contextual communication experience.

Transforming the Real Estate landscape with enhanced trust and safety.

(BUSINESS WIRE)--Nawy, the leading prop-tech platform in Africa that simplifies the buying, selling, and real estate investing journey for customers across Egypt, has announced a partnership with Truecaller, the global leader in communication verification and fraud prevention. This collaboration aims to enhance customer trust and elevate the communication experience in the real estate sector through Truecaller’s Customer Experience solution.

Nawy ensures seamless, secure, and transparent communication for customers throughout their real estate buying journey. By leveraging Truecaller’s Verified Business Caller ID-based solution, Nawy enhances its customer outreach with trusted branding elements like the verified badge, brand name, and logo. This ensures customers can quickly recognize and trust Nawy’s calls, leading to a seamless communication experience and improved engagement.

In today’s world consumers are overwhelmed by scams and fraudulent calls, and certain individuals not affiliated with Nawy have been contacting consumers, falsely claiming to represent the company. In light of this, Nawy reaffirms its commitment to providing the highest level of service to customers and ensuring their comfort by avoiding unnecessary disturbances through Truecaller’s Verified Business Caller ID, which also makes every interaction more authentic and memorable.

Using CX capabilities like Call Reason, Nawy adds valuable context to its calls, ensuring customers understand the purpose before answering.

Commenting on the partnership, Mohamed Abou Ghanima, Co-Founder and COO at Nawy, said: “Partnering with Truecaller reinforces the transparency we strive to provide for our customers. Unfortunately, our name has been used by others pretending to represent Nawy in an attempt to leverage the credibility and trust we have worked hard to build with our customers. These individuals have operated in ways that do not align with our values. By addressing this issue and collaborating with Truecaller, we aim to ensure that our customers can confidently identify genuine calls from Nawy representatives.”

Priyam Bose, Global Head of GTM and Developer Products at Truecaller added: "Truecaller is committed to fostering trust and safety in communication. Our Customer Experience solution empowers businesses like Nawy to deliver secure, seamless, and personalized communication, enabling users to engage confidently. We’re thrilled to partner with Nawy to redefine the customer experience in the African real estate ecosystem and look forward to supporting their journey to build trust and drive impactful engagement."

Truecaller’s Customer Experience Solution empowers business calls with brand identity and context, fostering reliable customer communication. Over 2,500 active businesses worldwide have benefited from the Verified Business Caller ID and other advanced communication capabilities. This solution enhances business call efficiency and significantly reduces phone call-related frauds and scams, promoting heightened customer safety in business communications.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241217954580/en/

Permalink

https://www.aetoswire.com/en/news/20241217954580r1

Contacts

 

press@truecaller.com

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

 HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia and Hypogammaglobulinemia

Administration of Recombinant Human Hyaluronidase Prior to Immunoglobulin Facilitates Subcutaneous Infusion of Larger Volumes, Potentially Reducing Frequency and Giving Patients More Flexibility

Approval Expands Takeda’s Portfolio of Differentiated Immunoglobulin Therapies and Reflects the Company’s Commitment to Bring High-Quality Plasma-Derived Therapies to Patients in Japan

 

(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID)2. The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan.

HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20). The administration of rHuPH20 increases the dispersion and absorption of immunoglobulin (IG) in the subcutaneous tissue, allowing larger volumes to be infused in the infusion site. This allows for less frequent dosing compared to other subcutaneous IG products, while avoiding the need for venous access. The ability to infuse a larger infusion volume is expected to increase administration flexibility for patients with agammaglobulinemia or hypogammaglobulinemia by decreasing the dosing frequency to once every 3 or 4 weeks, as compared to weekly or bi-weekly with conventional SCIG treatments.

The approval is based on data from two pivotal Phase 3, open-label, non-controlled studies evaluating the efficacy, safety, tolerability and pharmacokinetics in Japanese subjects with PID (NCT05150340, NCT05513586). In these studies, the efficacy and safety profile of HYQVIA in 16 patients aged 2 years or older in Japan were evaluated based on the results of the clinical trials. The Geo Mean of IgG trough level at the last 3 visits was 9.494g/L and was maintained at level comparable to treatment with intravenous or subcutaneous immunoglobulin (Geo Mean of IgG trough level 9.624g/L). The major adverse reactions were pyrexia 5 patients (31.3%) and infusion site erythema, injection site erythema, infusion site swelling, infusion site pain, and headache (12.5%)1. Data from two Phase 3 clinical trials conducted in patients with PID in North America (NCT00814320, NCT01175213) was also included in the submission.

“We are delighted that HYQVIA, approved in more than 40 countries worldwide, has now been approved in Japan,” said Naoyoshi Hirota, Regional Head of Research & Development for Takeda’s Plasma-Derived Therapies Business Unit in Japan. “The subcutaneous IG therapies currently available in Japan for patients with agammaglobulinemia or hypogammaglobulinemia require infusion once every week or every 2 weeks. We are proud to offer Japanese patients the first and only facilitated subcutaneous treatment option that offers a reduced dosing frequency of every 3 or 4 weeks.”

“There is a high unmet need for plasma-derived therapies (PDTs) in patients in Japan, which is anticipated to increase as education and timely diagnosis rates continue to improve,” said Kristina Allikmets, head of research & development for Takeda’s Plasma-Derived Therapies Business Unit. “The approval of HYQVIA, the first and only facilitated SCIG treatment, is further evidence of Takeda’s commitment to add to the standard of care for patients in Japan. We look forward to continuing to bring new therapeutic options that support and enhance the experience of patients in our home country throughout the next decade.”

With this approval, Takeda is now able to offer a range of SCIG therapies to patients based on their individual administrative needs, reflecting the company’s commitment to offer patients in Japan a broader choice of treatment options. It also follows the announcement of a significant investment to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan. HYQVIA is also currently under review in Japan for additional indications.

About Agammaglobulinemia or Hypogammaglobulinemia

Agammaglobulinemia is an inherited disorder caused by a gene defect that blocks the growth of normal, mature immune cells called B lymphocytes3. Hypogammaglobulinemia is a condition in which patients have low levels of antibodies due either to inherited genetic conditions (PID) or secondary effects (SID) – like chemotherapy, certain comorbid disorders, or immunosuppressants2. Individuals with any form of antibody deficiency frequently experience recurring and/or severe infections, and immunoglobulin replacement therapy can increase the level of antibodies in the body.

About Primary Immunodeficiency and Secondary Immunodeficiency

Primary immunodeficiency describes a heterogeneous group of more than 480 rare genetic diseases wherein part of the immune system is missing or not functioning properly4. Secondary immunodeficiency is defined as an acquired impairment of the immune response resulting from an underlying condition or factors extrinsic to the immune system. SID may occur as a consequence of malnutrition, metabolic disorders, use of immunosuppressive medications, chronic infections, malignancies, or severe trauma5. Due to their impaired immune system, patients with PID and SID may be more susceptible to infection, and it may take longer to recover from it. In patients with antibody deficiency and increased susceptibility and/or persistent infections, substitution with functional antibodies (immunoglobulin replacement therapy) is the standard of care to support the immune system's functioning5.

About HYQVIA®

HYQVIA is the combination product for subcutaneous injection containing one each vial of Subcutaneous Immunoglobulin 10% (SCIG10%) and Recombinant Human Hyaluronidase PH20 (rHuPH20). As of May 2024, HYQVIA has been approved in more than 40 countries worldwide.

HYQVIA Product Overview in Japan

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

______________________________

REFERENCES

1 HYQVIA 10% Subcutaneous Injection Set Package Insert in Japan.

2 Pimenta et al. Hypogammaglobulinemia: a diagnosis that must not be overlooked. BJMBR. 2019;52(10): e8926.

3 National Organization for Rare Disorders https://rarediseases.org/rare-diseases/agammaglobulinemia/

4 Tangye et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473-1507.

5 Tuano KS, Seth N, Chinen J. Secondary immunodeficiencies: An overview. Ann Allergy Asthma Immunol. 2021;127(6):617-626.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241219442534/en/

Permalink

https://www.aetoswire.com/en/news/2712202443786

Contacts

Media:

International Media

Kristine Kelly

Kristine.Kelly@takeda.com

+41 79 268 68 21

Japanese Media

Shigeyuki Matsui

Shigeyuki.Matsui@takeda.com

+81 (80) 3594-2460

Leading Travel Marketplace WINGIE Unveils Key Travel Insights for 2024

 

DUBAI, United Arab Emirates and RIYADH, Saudi Arabia, Dec. 25, 2024 (GLOBE NEWSWIRE) -- The leading online travel marketplace, WINGIE, experienced a remarkable growth in 2024, with bookings doubling compared to 2023. It reflects the increasing demand for travel, supported by data showing a steady rise in bookings, heightened traveler activity, and growing consumer confidence in global mobility.

WINGIE’s data revealed an average basket amount of $191, with Cairo emerging as the most popular destination, accounting for 28% of total bookings. Riyadh followed with 14%, Jeddah with 11%, Dammam with 10%, and Dubai with 7%. The busiest travel routes included Riyadh to Jeddah, which claimed 14% of bookings, followed by Jeddah to Cairo at 12%, Jeddah to Riyadh at 10%, and Cairo to Jeddah at 9%.

This year also saw incredible value for budget-conscious travelers. The most affordable ticket was priced at just $7.95 for a Tashkent to Samarkand flight, while the most expensive reached $11,562 for a Jeddah to London route.

Solo travel emerged as a dominant trend, with 74% of users opting to travel alone, while the remaining 26% traveled in groups of two or more. Booking behavior highlighted a preference for one-way tickets, which 57% of travelers chose, while roundtrip tickets accounted for 43%.

Wingie also provided insights into its user demographics. Men represented 63% of its customers, with women making up 37%. Additionally, 90% of its travelers were adults, 8% were children, and 2% were infants.

As a trusted platform connecting people with their dream destinations, WINGIE continues to lead the way in offering seamless and affordable travel experiences.

About Wingie Enuygun Group

Wingie Enuygun Group is a leading travel marketplace in the MENA region, specializing in flights through its platforms wingie.com, sa.wingie.com, wingie.ae and enuygun.com. The company offers a comprehensive range of travel products including flights, hotels, rental cars and bus tickets. Recognized for its innovation, Wingie Enuygun Group is at the forefront of the MENA online travel space, pioneering technological advancements and driving digital transformation within the industry.

Wingie leverages advanced AI technology to provide a seamless user experience, featuring virtual interlining for flights and a diverse array of airline tickets and travel content. The platform is available in six languages, employs over 400 people, and attracts approximately 200 million visitors annually, reaffirming its position as a premier choice for travelers.

Contact: marketing@wingie.com

Copyright © 2024 GlobeNewswire, Inc.